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Introduction
Optic neuritis (ON) is related to an inflammatory demy-
elination of the optic nerve that predominantly affects 
young adults and usually presents as a painful unilateral 
impairment of vision.1 ON may occur in isolation or be 
the first clinical sign of multiple sclerosis (MS). 
Furthermore, ON frequently occurs in MS patients in the 
clinical course.1 Usually, magnetic resonance imaging 
(MRI) is used in the evaluation of patients with sus-
pected ON as it very sensitive in detecting the sympto-
matic lesion2 and useful to check for associated 
asymptomatic white matter lesions.3 Besides contrast-
enhanced fat-suppressed T1-weighted images, fluid-
attenuated inversion recovery (FLAIR) images have 
additional value in evaluating the optic nerve.4,5 
Moreover, contrast-enhanced FLAIR images are much 
more sensitive than T1-weighted images for detecting 
low concentrations of gadolinium in the cerebrospinal 
fluid (CSF).6 In particular, in diseases affecting the lep-
tomeningeal compartment, contrast-enhanced FLAIR 
images have been shown to be useful to demonstrate the 
leptomeningeal pathology such as bacterial meningitis, 
meningeal carcinomatosis, and meningeal angiomato-
sis.7–11 In 2004, the hyperintense acute reperfusion 
marker was described in acute ischemic stroke for the 
first time.12 The phenomenon is caused by blood–brain 
barrier disruption following acute recanalization, reper-
fusion, and consecutive delayed gadolinium contrast 
enhancement in the subarachnoid space on FLAIR 
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images. Meanwhile, leptomeningeal contrast enhance-
ment on FLAIR images has also been reported in patients 
with MS and interpreted as a biomarker of inflamma-
tion,13,14 and there is increasing evidence that leptome-
ningeal inflammation might play an important role in the 
development of cerebral cortical gray matter pathology 
in MS.15 Protein accumulation, antigen presentation, and 
stimulation of reactive cells may promote a sustained 
leukocyte presence in the brain resulting in the forma-
tion of ectopic lymphoid-like tissue.16 While this has 
been primarily described in patients with primary- or 
secondary-progressive MS,15,16 signs of leptomeningeal 
inflammation on contrast-enhanced FLAIR images have 
been reported in approximately 20% of patients with 
relapsing–remitting MS.13,14 As Absinta et al. demon-
strated, the histopathological basis of these MRI find-
ings is leptomeningeal perivascular inflammation 
including T cells, B cells, and macrophages.13
However, so far no reports have been published on 
contrast enhancement in the perioptic subarachnoid 
space on FLAIR images in patients with ON. We 
therefore conducted a prospective study with special 
emphasis on this finding and here report the preva-
lence and distribution of perioptic leptomeningeal 
enhancement on contrast-enhanced fat-suppressed 
FLAIR images in patients with ON as well as clinical 
and laboratory associations.
Methods
Patients and controls
The study received approval (2015-552N-MA) from 
the institutional review board (IRB), and all partici-
pants provided written informed consent. After com-
pleting enrollment of patients with ON, the protocol 
was amended and again approved by the IRB for 
enrollment of additional control subjects without ON.
In the study period, 42 patients with clinically sus-
pected ON were included in the study. The diagnosis 
was based on clinical symptoms at presentation and 
during hospitalization corroborated by imaging and 
laboratory findings. Eight patients were excluded 
from the analysis due to a final diagnosis other than 
ON. In addition, the patients’ brain MRI and labora-
tory test results were reviewed with special focus on 
acute and chronic white matter lesions and CSF find-
ings, respectively (CSF-specific oligoclonal bands, 
CSF IgG index, CSF pleocytosis (white blood count 
(WBC) >5/mm3), and CSF protein elevation (protein 
>45 mg/dL)). After diagnostic workup, patients were 
diagnosed either with MS according to the 2010 revi-
sion of the McDonald criteria, with clinically isolated 
syndrome, or, if no additional white matter lesions 
were present, with isolated ON.
The control group consisted of patients who under-
went MRI for different reasons such as suspected 
ischemic stroke, follow-up of untreated or treated 
intracranial aneurysms, or follow-up after surgery of 
acoustic neurinoma, glioma, meningioma, or arterio-
venous malformations. None of these patients had a 
history of ON or demyelinating disease.
MRI
All patients underwent MRI performed on a 1.5 T scan-
ner (Magnetom Avanto; Siemens Medical Systems, 
Erlangen, Germany) using a standardized MRI protocol 
including (1) transverse, coronal, and sagittal localizing 
sequences; axial (2) T1-weighted images; (3) FLAIR 
images; followed by thin-section (3 mm) axial (4) fat-
suppressed T1-weighted images; (5) fat-suppressed 
FLAIR images (field of view 230 mm×169 mm, matrix 
256 mm×164 mm, number of slices 24, TR 9000 ms, TE 
89 ms, TI 2500 ms, spectral fat saturation, acquisition 
time: 2:26 minutes:seconds); as well as thin-section 
(3 mm) coronal (6) fat-suppressed T1-weighted images; 
(7) T2-weighted images; and (8) fat-suppressed FLAIR 
images (field of view 230 mm×169 mm, matrix 
256 mm×168 mm, number of slices 24, TR 9000 ms, TE 
89 ms, TI 2500 ms, spectral fat saturation, acquisition 
time: 2:26 minutes:seconds). After manual injection of 
single-dose contrast agent (gadoteric acid (Dotarem; 
Guerbet, Aulnay-sous-Bois, France), (9) T1-weighted 
images identical to (2); (10) and (11) T1-weighted 
images identical to (4) and (6); as well as (12) and (13) 
fat-suppressed FLAIR images identical to (5) and (8) 
were completed. Correspondingly, thin-section axial 
and coronal fat-suppressed FLAIR images before and 
after intravenous contrast agent application were added 
to the routinely performed MRI protocol in the control 
group. The axial and coronal FLAIR sequences were 
acquired approximately 10 and 12 minutes after intrave-
nous contrast agent application.
MRI analysis
All MRI scans were reviewed in consensus by two 
readers (L.P.-L. and A.F. with 1 and 11 years’ experi-
ence in neuroimaging) with regard to morphology and 
signal characteristics in the optic nerve (swelling or 
increased signal intensity), lesion location (intraorbital, 
canalicular, or cranial part), enhancement in the optic 
nerve on contrast-enhanced T1-weighted images, peri-
optic leptomeningeal enhancement on contrast-
enhanced fat-suppressed FLAIR images, as well as 
acute white matter lesions on contrast-enhanced 
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T1-weighted images and chronic white matter lesions 
on FLAIR images.
Statistical analysis
All statistical analyses were performed using 
Statistical Product and Service Solutions (SPSS) sta-
tistics for Windows (Release 17.0; SPSS, Chicago, 
IL, USA). Descriptive and clinical data was analyzed 
using χ2-based tests (sex, symptoms, diagnosis) or the 
Mann–Whitney U test (age, duration of symptoms) as 
appropriate. MRI findings were analyzed using χ2-
based tests (presence of T2 lesion, contrast enhance-
ment, perioptic leptomeningeal enhancement, 
additional hyperintense brain lesions). CSF analysis 
results were analyzed using χ2-based tests (CSF-
specific oligoclonal bands, CSF pleocytosis, CSF pro-
tein elevation) or the Mann–Whitney U test (CSF IgG 
index) as appropriate. All statistics was performed 
with a 0.05 level of significance.
Results
Patient demographics
A total of 34 patients with final diagnosis of unilateral 
ON were analyzed in detail. The median age was 30 
(IQR: 25–41.5) years; 7 (20.6%) patients were male 
and 27 (79.4%) patients were female. Among the ON 
patients, there were four (11.8%) patients with a his-
tory of MS. Of the remaining 30 patients, further 6 
(20%) were diagnosed with MS according to the 2010 
revision of the McDonald criteria, 14 (46.7%) were 
diagnosed with clinically isolated syndrome, and 10 
(33.3%) were diagnosed with isolated ON. In none of 
the patients, diagnostic workup indicated other causes 
of ON such as autoimmune disorders or infectious 
diseases. Clinical symptoms included sudden loss of 
vision (100%), pain with eye movement (50%), and 
loss of color vision (61.8%).
In the control group, 20 patients were included. The 
median age was 43.5 (IQR: 29–49.5) years; 6 (30%) 
patients were male and 14 (70%) patients were 
female.
MRI findings
MRI was performed within a median time of 3 (IQR: 
1–7) days after onset of symptoms. Overall, a lesion in 
the optic nerve consistent with unilateral ON could be 
identified in 29 (85.3%) patients on MRI. In 13 
(38.2%) patients, the lesion was located in the intraor-
bital part of the optic nerve; in 5 (14.7%) patients in 
the intraorbital and canalicular part; in 2 (5.9%) 
patients in the canalicular part; in 5 (14.7%) patients in 
the canalicular and cranial part; and in 4 (11.8%) 
patients in the cranial part of the optic nerve. On con-
trast-enhanced fat-suppressed FLAIR images, 25 
(73.5%) patients with ON demonstrated perioptic lep-
tomeningeal enhancement (see Figures 1 and 2), and 
in 3 (8.8%) patients this was even the only pathologi-
cal finding (see Figure 3). A perioptic leptomeningeal 
enhancement was more frequently found on coronal 
FLAIR images (100%) compared to axial FLAIR 
images (13/25 (52%)). In the contralateral optic nerve, 
none of the ON patients demonstrated perioptic lep-
tomeningeal enhancement on contrast-enhanced fat-
suppressed FLAIR images (see Figures 1 and 2). In 19 
(55.9%) patients, a pathological hyperintense signal or 
swelling of the optic nerve could be demonstrated on 
T2-weighted images. A pathological enhancement in 
the optic nerve on contrast-enhanced T1-weighted 
images was found in 23 (67.6%) patients. Of the 25 
patients with perioptic leptomeningeal enhancement, 
16 (64%) patients demonstrated signal alterations in 
the optic nerve on T2-weighted images as well as con-
trast enhancement on T1-weighted images, 6 (24%) 
patients demonstrated only contrast enhancement in 
the optic nerve on T1-weighted images, while the 
remaining 3 (12%) patients demonstrated neither sig-
nal alterations on T2-weighted images nor contrast 
enhancement on T1-weighted images. Of the nine 
patients without perioptic leptomeningeal enhance-
ment, three (33.3%) patients demonstrated only signal 
alterations in the optic nerve on T2-weighted images, 
one (11.1%) patient demonstrated only contrast 
enhancement in the optic nerve on T1-weighted 
images, while the remaining five (55.6%) patients 
demonstrated neither signal alterations on T2-weighted 
images nor contrast enhancement on T1-weighted 
images. In ON patients with signal alterations or swell-
ing in the optic nerve, symptom duration was signifi-
cantly longer than in patients without (3 (2–7) vs 2 
(0–5); p = 0.036). Regarding the patients with and 
without perioptic leptomeningeal contrast enhance-
ment on fat-suppressed FLAIR images (p = 0.23) or 
contrast enhancement in the optic nerve on contrast-
enhanced T1-weighted images (p = 0.44), no differ-
ences in symptom durations could be found. Additional 
chronic white matter lesions on FLAIR images were 
observed in 22 (64.7%) patients, whereas acute white 
matter lesions with a pathological enhancement on 
contrast-enhanced T1-weighted images were found in 
only 1 (2.9%) patient.
In the control group, none of the patients demon-
strated perioptic leptomeningeal enhancement on 
contrast-enhanced fat-suppressed FLAIR images (see 
Figure 4.)
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In comparison, patients with perioptic leptomeningeal 
enhancement on contrast-enhanced fat-suppressed 
FLAIR images had a higher prevalence of additional 
hyperintense brain lesions (p = 0.022) as well as CSF-
specific oligoclonal bands (p = 0.013) than patients 
without. With regard to clinical presentation, duration 
of symptoms, as well as CSF IgG index, pleocytosis, 
and protein, no significant differences were observed 
between both groups (see Tables 1 and 2 for details). 
Regarding the patients who demonstrated perioptic 
leptomeningeal enhancement on contrast-enhanced 
fat-suppressed FLAIR images as the only pathological 
Figure 1. Perioptic leptomeningeal enhancement in a 38-year-old patient with optic neuritis. In comparison, (a) native 
(upper row) and contrast-enhanced fat-suppressed thin-section axial FLAIR images (lower row) as well as (b) native 
(upper row) and contrast-enhanced fat-suppressed thin-section coronal FLAIR images (lower row) show perioptic 
leptomeningeal enhancement (arrows). The contralateral optic nerve is unremarkable.
Figure 2. Extensive perioptic leptomeningeal enhancement in a 37-year-old patient with optic neuritis. In comparison, 
(a) native (upper row) and contrast-enhanced fat-suppressed thin-section axial FLAIR images (lower row) as well as (b) 
native (upper row) and contrast-enhanced fat-suppressed thin-section coronal FLAIR images (lower row) show perioptic 
leptomeningeal enhancement (arrows). The contralateral optic nerve is unremarkable.
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Figure 3. Perioptic leptomeningeal enhancement as the only pathological finding in a 30-year-old woman with optic 
neuritis. In comparison, (a) native (upper row) and contrast-enhanced (lower row) coronal T1-weighted images reveal 
no contrast enhancement in the left optic nerve. In comparison, (b) and (c) native (upper row) and contrast-enhanced 
fat-suppressed thin-section coronal FLAIR images (lower row) in two consecutive planes demonstrate perioptic 
leptomeningeal enhancement as the only pathological finding (arrows). Note the chronic white matter lesion in the left 
hemisphere (arrowhead).
Figure 4. The optic nerve in a 56-year-old control subject. In comparison, (a) native (upper row) and contrast-enhanced 
fat-suppressed thin-section axial FLAIR images (lower row) as well as (b) native (upper row) and contrast-enhanced fat-
suppressed thin-section coronal FLAIR images (lower row) show no perioptic leptomeningeal enhancement.
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finding, two of these showed additional hyperintense 
brain lesions on FLAIR images and were diagnosed 
with clinically isolated syndrome. One of these patients 
also had CSF-specific oligoclonal bands.
Discussion
In this study, we describe two novel and essential 
findings in ON: (1) a perioptic contrast enhancement 
on contrast-enhanced fat-suppressed FLAIR images 
is present in more than 70% of patients with ON and 
(2) in some cases, this perioptic contrast enhancement 
may be the only pathological finding. Thus, the perio-
ptic contrast enhancement on fat-suppressed FLAIR 
images might indicate that the inflammatory process 
in ON is not only restricted to the optic nerve but may 
also affect the leptomeningeal compartment. 
Furthermore, the observation of perioptic contrast 
enhancement as the only pathological finding in a 
subset of ON patients might imply that the inflamma-
tion possibly even started in the leptomeningeal com-
partment and spread to the optic nerve in the course of 
disease corresponding to the recently published 
observations in MS. Another explanation of perioptic 
leptomeningeal contrast enhancement might be the 
mere diffusion of contrast agent from a pronounced 
inflammation in the optic nerve to the adjacent perio-
ptic leptomeningeal compartment. Nevertheless, this 
does not explain isolated perioptic leptomeningeal 
contrast enhancement in a subset of ON patients with-
out contrast enhancement in the optic nerve in this 
study.
More than a decade ago, Hickman et al.17 already 
described optic nerve sheath enhancement in a subset 
of ON patients on triple-dose contrast-enhanced 
T1-weighted images. Enhancement of the optic nerve 
sheath was observed in approximately 75% of 
patients. Since then, this specific finding has not been 
in the focus of clinical studies but has been reported 
rather as a secondary finding in a few smaller studies 
on MRI in ON.18,19 However, the frequency of a peri-
optic enhancement is lower in the more recent studies 
than in the initial study.18 An explanation might be the 
Table 1. Characteristics of optic neuritis patients with perioptic leptomeningeal enhancement on contrast-enhanced fat-
suppressed FLAIR images.
All, n = 34 Contrast enhancement p value
 Yes, n = 25 No = 9
Age (years), median (IQR) 31 (25–42.5) 30 (25–41) 32 (23–44) 0.97
Male sex, n (%) 7 (20.6) 4 (16) 3 (33.3) 0.27
Duration of symptoms (days), 
median (IQR)
3 (1–7) 3 (2–7) 2 (0.5–4) 0.23
Clinical presentation
 Sudden loss of vision, n (%) 34 (100) 25 (100) 9 (100) NA
 Pain with eye movement, n (%) 17 (50) 12 (48) 5 (55.6) 0.70
 Loss of color vision, n (%) 21 (61.8) 15 (60) 6 (66.7) 0.72
MRI findings
 T2 lesion in the optic nerve, n (%) 19 (55.9) 16 (64) 3 (33.3) 0.11
 Contrast enhancement in the 
optic nerve, n (%)
23 (67.6) 22 (88) 1 (11.1) <0.001
  Additional hyperintense brain 
lesions, n (%)
22 (64.7) 19 (76) 3 (33.3) 0.022
Diagnosis
 Isolated optic neuritis, n (%) 10 (29.4) 5 (20) 5 (55.6) 0.13
 Clinically isolated syndrome, n (%) 14 (41.2) 12 (48) 2 (22.2)  
 Multiple sclerosis, n (%) 10 (29.4) 8 (32) 2 (22.2)  
CSF analysis, available in 25
 Oligoclonal bands, n (%) 15 (60) 14 (73.7) 1 (16.7) 0.013
 IgG index, median (IQR) 0.62 (0.56–0.9825) 0.645 (0.575–1.4675) 0.575 (0.45–0.7025) 0.077
 Pleocytosis, n (%) 12 (48) 11 (57.9) 1 (16.7) 0.078
 Protein elevation, n (%) 6 (24) 3 (15.8) 3 (50) 0.087
CSF: cerebrospinal fluid; IgG: immunoglobulin G; IQR: interquartile range; WBC: white blood count; FLAIR: fluid-attenuated 
inversion recovery; MRI: magnetic resonance imaging; NA: not applicable.
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fact that triple-dose contrast-enhanced MRI is nowa-
days not generally recommended in patients with ON 
or MS20 resulting in a lower detection rate. Contrast-
enhanced FLAIR images in turn have the advantage 
of a considerably higher sensitivity for minute con-
centrations of gadolinium-based contrast agents in the 
subarachnoid space6 and therefore might complement 
MRI protocols when a special focus shall be laid upon 
the perioptic enhancement in ON. Interestingly, other 
studies described a more extensive inflammation of 
the perioptic soft tissue on contrast-enhanced 
T1-weighted images in up to one third of ON patients 
with antibodies against myelin oligodendrocyte gly-
coprotein.21,22 These patients differed significantly 
from the patients in this study with regard to clinical 
(most cases with recurrent or bilateral ON) as well as 
radiological aspects (extensive involvement of the 
perioptic soft tissue, different white matter lesion pat-
tern). Nevertheless, contrast-enhanced fat-suppressed 
FLAIR images could be useful for a more detailed 
characterization of the perineural inflammation in 
these ON patients as well.
Besides the above-mentioned pathophysiological con-
siderations, and aspects concerning possible future 
studies, inclusion of contrast-enhanced fat-suppressed 
FLAIR images in routine MRI protocols could be a 
valuable addition in patients with suspected ON in 
daily clinical practice since perioptic contrast enhance-
ment on FLAIR images was a frequent and in some 
cases even the only pathological MRI finding in ON.
Contrast enhancement in the optic nerve has been 
observed in two thirds of ON patients in this study. It 
is thought to reflect the acute inflammation and 
blood–brain barrier impairment and has been demon-
strated in up to 94.4% of ON patients in previous 
studies.2 However, in more recently published stud-
ies, the frequency of contrast enhancement ranged 
markedly lower between 66.7% and 85%.17,18,23,24
Signal alterations or swelling in the optic nerve on 
T2-weighted images were observed in approximately 
half of the patients with ON in this study. This is also 
lower in comparison with previous studies reporting 
signal alterations or swelling in the optic nerve in 
79.8% to 100%.17,18,24,25 Possibly, this observation can 
be attributed at least partly to the fact that in this study, 
ON patients underwent MRI at an early stage of dis-
ease within a median of 3 days after symptom onset 
which is earlier than in the other studies in which ON 
patients underwent MRI within a median of 5 days,24 
13 days,17,23 or 21 days.25 In another study, a range of 
7–45 days from symptom onset to MRI has been 
reported.18 In MS lesions in the brain, Kermode et al.26 
showed that contrast enhancement may precede 
lesion appearance on T2-weighted images. Thus, the 
observed discrepancy between this study and previous 
studies may be explained by the different time points 
of MRI examination. This consideration might also be 
corroborated by the finding of this study that ON 
patients with signal alteration or swelling in the optic 
nerve had a significantly longer time from symptom 
onset to MRI compared to those ON patients without. 
However, to our best knowledge, there are no studies 
that investigated systematically the temporal evolution 
of optic nerve lesions in ON on MRI, and, regrettably, 
a follow-up MRI was not included in this study.
Table 2. Characteristics of optic neuritis patients who underwent a lumbar puncture.
All, n = 34 Lumbar puncture p value
 Yes, n = 25 No = 9
Age (years), median (IQR) 31 (25–42.5) 30 (25–41.5) 33 (19.5–56) 0.97
Male sex, n (%) 7 (20.6) 6 (24) 1 (11.1) 0.41
Duration of symptoms (days), median (IQR) 3 (1–7) 3 (2–7) 2 (0.5–3) 0.09
MRI findings
 T2 lesion in the optic nerve, n (%) 19 (55.9) 16 (64) 3 (33.3) 0.11
 Contrast enhancement in the optic nerve, n (%) 23 (67.6) 17 (68) 6 (66.7) 0.94
 Perioptic leptomeningeal enhancement, n (%) 25 (73.5) 19 (76) 6 (66.7) 0.59
 Additional hyperintense brain lesions, n (%) 22 (64.7) 18 (72) 4 (44.4) 0.14
Diagnosis
 Isolated optic neuritis, n (%) 10 (29.4) 5 (20) 5 (55.6) 0.06
 Clinically isolated syndrome, n (%) 14 (41.2) 13 (52) 1 (11.1)  
 Multiple sclerosis, n (%) 10 (29.4) 7 (28) 3 (33.3)  
IQR: interquartile range; MRI: magnetic resonance imaging.
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This study has some limitations. First, this is a clinical 
study of moderate sample size. Nevertheless, to our 
knowledge, this is the first series investigating the 
additional value of leptomeningeal enhancement on 
contrast-enhanced fat-suppressed FLAIR images in 
ON. Second, we did not perform a follow-up MRI. 
Consequently, we cannot provide information on the 
course of perioptic leptomeningeal contrast enhance-
ment in ON. Despite these limitations, the study has 
several strengths including the prospective study 
design with a standardized MRI protocol and MRI 
examinations on one scanner type.
Perioptic leptomeningeal contrast enhancement on 
FLAIR images is a novel marker in ON and possibly 
reflects a leptomeningeal inflammatory process pre-
ceding or accompanying ON. Consequently, inclu-
sion of contrast-enhanced fat-suppressed FLAIR 
images in MRI protocols for patients with suspected 
ON might be a useful addition.
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